i-Base home
Search Menu
  • Home
  • HTB
  • 2018
  • May
  • 21

HTB

21 May 2018

Contents

Editorial

  • 21 May 2018: vol 19 no 9: DTG Alert and BHIVA/BASHH reports

Treatment alerts

  • Potential safety signal for dolutegravir from the time of conception

Conference reports

  • Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)
  • Low PEP and PrEP awareness among trans people in London and their partners
  • Low awareness of PrEP in BME communities in Leeds but high interest in use
  • Younger people living with HIV more likely to have a positive self image
  • Zero or negligible risks of HIV, HBV or HCV transmission by biting or spitting
  • UK-CAB community representation on guideline panels and research studies

Treatment access

  • Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries
  • Generic manufacturers from South Africa and South Korea join Medicine Patent Pool (MPP)
  • WHO releases first list for essential diagnostics
  • Campaign forces Government U-turn on linking NHS data to immigration service

Pregnancy

  • Dolutegravir in pregnancy: early data reassuring but ongoing surveillance is still essential

Paediatric care

  • FDA guidance for developing paediatric ARVs: online for comment (2018)

OIs, coinfections and complications

  • US study tracks kidney transplant results from HIV positive donors

Basic science and immunology

  • New online animation of HIV lifecycle

Other news

  • St Stephen’s AIDS Trust to close after 30 years of HIV research

PDFs

  • 21 May 2018: vol 19 no 9
  • HTB RSS

Early access

  • Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021) 15 January 2021
  • Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study       14 January 2021
  • Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early 10 January 2021
  • Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico 10 January 2021
  • All early access reports

Current issues

  • January 2021
  • December 2020
  • November 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook